35 companies turning fundamental research into commercial reality. Filter by sector, and open any company to read the science.
Small-molecule therapies built on a mitochondrial mechanism.
Ensilication that removes the cold chain from biopharma.
Dual-silencing RNAi to cut heart-attack and stroke risk.
Implantable electric-field therapy for glioblastoma.
Multi-cancer early detection from a single blood test.
AI drug-target discovery from genomic outliers.
Harnessing the breast-milk microbiome for infant health.
Longer-acting, protective eye-drop technology.
AI that helps radiologists diagnose prostate cancer.
Small-molecule antivirals against RNA viruses.
Antibiofilm drugs that make antibiotics work again.
Clinical decision support for epilepsy diagnosis.
Needle-free continuous glucose monitoring.
3D-printed spinal fusion for reliable fixation.
Generative-AI photorealistic sign-language translation.
Digitising and automating chemistry R&D.
Field-ready high-energy pulsed laser platforms.
Fibre-to-chip connectors for AI datacentres.
Semiconductor platforms for neural interfaces.
Benchtop single-molecule fluorescence instruments.
A direct-cycle modular high-temperature reactor.
Bio-inspired smart sensors for space and defence.
3D-printed cementless knee implants.
Flexible digital X-ray film for hard-to-reach imaging.
Smart glass coatings for passive cooling.
Bio-based adhesives engineered from peptides.
Digital quality assurance for 3D-printed parts.
Turning CO2 into high-value silica and materials.
Selective recovery of critical and precious metals.
Low-carbon ingredients from agricultural side-streams.
Dry-coated battery electrodes for low-cost EVs.
Europe's leading stellarator fusion company.
High-efficiency heat pumps for industrial heat.
Modular reactors that turn wastewater into energy.
Predictable tidal-stream power for grid balancing.
We invest in exceptional founders working on cutting-edge technologies, and we understand the science well enough to move before the crowd.
